CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology is based in IRVINE, Calif.
| Revenue (Most Recent Fiscal Year) | $4.04M |
| Net Income (Most Recent Fiscal Year) | $-160.99M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1079.68 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.50 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -3602.68% |
| Net Margin (Trailing 12 Months) | -3602.68% |
| Return on Equity (Trailing 12 Months) | -25.20% |
| Return on Assets (Trailing 12 Months) | -23.98% |
| Current Ratio (Most Recent Fiscal Quarter) | 22.22 |
| Quick Ratio (Most Recent Fiscal Quarter) | 22.20 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 8.29 |
| Book Value per Share (Most Recent Fiscal Quarter) | $11.61 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.90 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.08 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.69 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 88.64M |
| Free Float | 84.39M |
| Market Capitalization | $6.72B |
| Average Volume (Last 20 Days) | 0.75M |
| Beta (Past 60 Months) | 0.24 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 26.56% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |